Compound

    DIM

    3,3-Diindolylmethane

    TL;DR

    DIM is a cruciferous vegetable metabolite that shifts oestrogen metabolism toward 2-hydroxy metabolites. That biochemical effect is well demonstrated at 100-300 mg/day; whether it translates into clinical benefit for hormonal symptoms, acne or cancer risk is not established.

    Ideal For

    • People exploring oestrogen metabolism support with realistic expectations
    • Adjunct interest alongside a cruciferous-rich diet

    Avoid If

    • Using hormonal contraception
    • Pregnancy or breastfeeding
    • Oestrogen-receptor-positive cancer, unless oncologist-directed
    • Taking narrow therapeutic index drugs metabolised by CYP1A2

    Frequently Asked Questions

    Overview

    DIM sits at an awkward point between a validated biomarker effect and an unproven clinical one. The biochemistry is not in dispute: DIM induces CYP1A1, shifting oestradiol metabolism toward 2-hydroxyoestrone and away from 16-alpha-hydroxyoestrone, and this ratio shift is reliably measurable in urine at supplemental doses. The interpretive leap comes next. The 2-hydroxy pathway has been characterised as the more favourable one on the basis of observational associations with breast cancer risk, but interventional evidence that changing the ratio changes outcomes is thin. Trials in cervical intraepithelial neoplasia have been mostly null, prostate work is early, and the popular uses — hormonal acne, oestrogen dominance, PMS, post-cycle support in bodybuilding — rest largely on mechanism and testimonial. DIM is also a genuine CYP inducer, which makes the interaction profile more serious than most supplements: hormonal contraceptives are the obvious concern. A harmless quirk worth knowing is that it turns urine orange.

    How It Works

    • Aryl hydrocarbon receptor ligand; induces CYP1A1
    • Shifts oestrogen metabolism toward 2-hydroxy metabolites
    • Weak aromatase inhibition and androgen receptor antagonism
    • CYP induction underlies both the effect and the interaction risk

    Quick Facts

    • Shifts oestrogen metabolite ratio reliably; clinical benefit unproven
    • Cervical dysplasia trials were largely null
    • Can reduce hormonal contraceptive effectiveness
    • Turns urine orange, which is harmless

    Supporting Research
    5 studies

    Effect of Diindolylmethane Supplementation on Low-Grade Cervical Cytological Abnormalities: Double-Blind, Randomised, Controlled Trial

    Score: 9/10
    2012
    rct
    n=551

    Castanon A, Tristram A, Mesher D +6 more

    No significant difference between DIM and placebo in cytology, colposcopic impression, HPV clearance or CIN2+ rates.

    View source

    Developing phytoestrogens for breast cancer prevention

    Score: 5/10
    2012
    systematic_review

    Phytoestrogens and related dietary compounds act as weak aromatase inhibitors with inconsistent clinical outcomes.

    View source

    A Randomized, Placebo-Controlled Trial of Diindolylmethane for Breast Cancer Biomarker Modulation in Patients Taking Tamoxifen

    Score: 8/10
    2017
    rct
    n=130

    Thomson CA, Chow HHS, Wertheim BC +5 more

    DIM increased the urinary 2:16-alpha-hydroxyoestrone ratio and lowered endoxifen concentrations.

    View source

    Oral Diindolylmethane (DIM): Pilot Evaluation of a Nonsurgical Treatment for Cervical Dysplasia

    Score: 6/10
    2010
    rct
    n=64

    Del Priore G, Gudipudi DK, Montemarano N +3 more

    Improvement rates did not differ significantly between DIM and placebo in CIN 2 or 3.

    View source

    Pilot Study: Effect of 3,3'-Diindolylmethane Supplements on Urinary Hormone Metabolites in Postmenopausal Women with a History of Early-Stage Breast Cancer

    Score: 4/10
    2004
    rct
    n=19

    Dalessandri KM, Firestone GL, Fitch MD +2 more

    DIM significantly increased the 2-hydroxyoestrone to 16-alpha-hydroxyoestrone ratio versus placebo.

    View source

    Safety Information

    Potential Side Effects

    Headache, nausea and gastrointestinal upset, more common above 300 mg/day. Harmless orange discolouration of urine. Rare reports of decreased sodium and, at high doses, hormonal symptom flares.

    Contraindications

    Not for use in pregnancy or breastfeeding. Anyone with hormone-sensitive cancer should only use it under oncology supervision, since altering oestrogen metabolism is not automatically beneficial.

    Drug Interactions

    • Hormonal contraceptives — CYP induction may reduce efficacy
    • Tamoxifen and aromatase inhibitors — unpredictable interaction; avoid without oncology input
    • CYP1A2 substrates such as clozapine and theophylline — altered levels
    • Caffeine — metabolism may be accelerated

    Pregnancy & Breastfeeding

    Pregnancy: likely_unsafe

    Breastfeeding: insufficient_data

    Dosage Guidelines

    Dosage Used in Studies

    100-300 mg

    Best Time to Take

    Once or twice daily with food

    Best Form

    Microencapsulated or bioavailability-enhanced DIM

    Bioavailability

    Crystalline DIM is very poorly absorbed; microencapsulated forms improve bioavailability several-fold.

    Forms Compared

    Microencapsulated DIM

    Indole-3-carbinol

    Cruciferous vegetables

    Food & Timing

    Take with a fat-containing meal; DIM is poorly water soluble.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.